論文・学術発表
ただいま製作中です。しばらくお待ちください。

2018年

The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.
Kido T, Miyagawa S, Goto T, Tamai K, Ueno T, Toda K, Kuratani T, Sawa Y.
PLoS One. 2018 Dec 5;13(12):e0202838.
ただいま製作中です。しばらくお待ちください。

2016年

Stem Cell Therapy for Epidermolysis Bullosa-Does It Work?
Tamai K, Uitto J.
J Invest Dermatol. 2016 Nov;136(11):2119-2121.

2015年

Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRα(+) mesenchymal cells from bone marrow.
Aikawa E, Fujita R, Kikuchi Y, Kaneda Y, Tamai K.
Sci Rep. 2015 Jun 5;5:11008.
Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.
Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, Kikuta J, McGrath JA, Uitto J, Ishii M, Iizuka H, Kaneda Y.
J Immunol. 2015 Feb 15;194(4):1996-2003.
Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice.
Fujita R, Tamai K, Aikawa E, Nimura K, Ishino S, Kikuchi Y, Kaneda Y.
Stem Cells. 2015 Mar;33(3):962-75.